Médecine

Paramédical

Autres domaines


S'abonner

O40: The effect of the national drug law reform on the incidence of 3,4-methylenedioxypyrovalerone (MDPV) among users of illegal drugs in Finland - 28/06/14

Doi : 10.1016/S2352-0078(14)70048-4 
P. Kriikku 1, 2, J. Rintatalo 3, L. Wilhelm 4, I. Ojanperä 1
1 Department of forensic medicine, Hjelt institute, university of Helsinki, Finland 
2 Vita laboratory, Vita health care services Ltd, Helsinki, Finland 
3 National bureau of investigation forensic laboratory, Vantaa, Finland 
4 LADR GmbH MVZ Dr. Kramer & colleagues, Geesthacht, Germany 

Résumé

Introduction

In 2010, the Finnish drug legislation was improved in order to be able to react to emerging new psychoactive substances (NPS) more effectively. The amended Narcotics Act allows for a more rapid categorization of NPS as illegal narcotics at the initiative of the Finnish government. In this study, we sought to examine the prevalence of MDPV among drivers suspected of driving under the influence of drugs (DUID) in Finland, before and after the amendment of the Narcotics Act. In addition, the prevalence of MDPV in medico-legal autopsy cases was assessed. MDPV is a novel psychoactive drug with stimulant effects. It has been exceptionally popular among users of illegal drugs in Finland. MDPV was the first drug to be scheduled according to the amended Narcotics Act.

Methods

Since August 2009, MDPV has been included in the screening of post-mortem toxicology samples in Finland. Accordingly, serum samples from suspected DUID offenders have been analyzed for the presence of MDPV since September 2009. The analysis of MDPV was carried out using LC-MS/MS (DUID) and GC-MS (post-mortem toxicology) systems that have been described in detail elsewhere. We studied the MDPV positive cases between 2009 and 2012. Also, the concomitant use of other psychoactive drugs and the demographics of the users were examined.

Results

In DUID cases, the total number of MDPV positive cases was 486. Of these, 214 were from the time before the scheduling of the substance. In autopsy cases the numbers were 38 and 18 respectively. The number of MDPV positives decreased both in DUID cases and in autopsied after the scheduling of the drug. In most cases, MDPV was detected among several other psychoactive substances, the most prevalent co-findings being amphetamine and benzodiazepines. The mean (median) serum concentration of MDPV in DUID cases was 0.11 (0.03)mg/L. The mean (median) postmortem blood concentration in autopsy cases was 0.55 (0.12)mg/L.

Conclusion

Contrary to the expectations of some experts, MDPV did not completely disappear from the market after its national scheduling as an illegal narcotic. Nevertheless, the number of cases both in DUID suspects and in post-mortem toxicology decreased after the amendment. As seen in some other similar studies, the chances to limit and control the use of new psychoactive drugs by means of national legislation are somewhat limited. However, if no measures are taken in terms of the legal status of NPS, the efficacy of the available methods of controlling distribution, and of limiting harm to users and non-users, will be marginal. It is crucial to act fast in defining the legal status and in informing authorities and consumers about the dangers associated with the drug. This cannot be accomplished without rapid measures in the analyzing laboratories to include new substances into the screening methods. Also, extensive scientific research on these substances must be encouraged in order to better identify potentially dangerous substances.

Le texte complet de cet article est disponible en PDF.

© 2014  Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 26 - N° 2S

P. S23 - juin 2014 Retour au numéro
Article précédent Article précédent
  • O39: Death by self-mutilation after cannabis consumption in a patient with cortical dysplasia
  • C. Sastre, V. Baillif-Couniou, M. Cheze, M. Deveaux, P. Kintz, M.D. Piercecchi-Marti, G. Leonetti, A.-L. Pelissier-Alicot
| Article suivant Article suivant
  • O41: Dark Web shopping: A case report of a cyanide suicide
  • G. Tournel, E. le Garff, L. Humbert, J.-F. Wiart, A. Garat, V. Hedouin, D. Allorge

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement ou un achat à l’unité.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.